- Hemodialysis patients tend to have denser blood clots than individuals without kidney disease.
- Dense blood clots were linked to an increased risk of premature death from cardiovascular and other causes.
Washington, DC (January 5, 2017) -- Dialysis patients may have altered blood clots that increase their risk of dying prematurely, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Kidney failure patients on dialysis have an elevated risk of dying early, especially from cardiovascular causes. Their blood also has altered coagulation properties, which increases their risk of both bleeding and thrombotic events such as stroke. Because of these risks, a team led by Katharina Schütt, MD and Georg Schlieper, MD (RWTH University Aachen, in Germany) investigated the impact of clot structure on health outcomes in hemodialysis patients.
When the researchers analyzed the blood of 171 chronic hemodialysis patients, they found that the patients tended to have a denser clot structure than individuals without kidney disease. In addition, patients with such compact clots had an increased risk of dying from cardiovascular causes as well as an increased risk of dying from other causes. Finally, dialysis patients' fibrinogen--a protein that is converted into fibrin during blood clot formation--exhibited certain modifications that were different from fibrinogen from patients without kidney disease.
"Whether better dialysis treatment or medication could improve clot structure needs to be investigated in future studies," said Dr. Schütt.
Study co-authors include Anna Savvaidis, MD, Sebastian Maxeiner, Katharina Lysaja, Vera Jankowski, PhD, Stephan Schirmer, MD, Nada Dimkovic, MD, Peter Boor, MD, Nadine Kaesler, PhD, Friedo Dekker, MD, Jürgen Floege, MD, and Nikolaus Marx, MD.
Disclosures: The authors reported no financial disclosures.
The article, entitled "Clot structure - a potent mortality risk factor in hemodialysis patients," will appear online at http://jasn.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 16,000 members representing 112 countries. For more information, please visit http://www.